Visu Finance

AZN - AstraZeneca Stock Is Up 10% on Tariff News. But Is the Pharmaceutical Giant a Buy?

Oct 02, 2025

fool.com

Shares of AstraZeneca (AZN -0.84%) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early breast cancer.

AZN - Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term

Oct 02, 2025

zacks.com

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

AZN - AstraZeneca shares leap with FDA set to review drug to treat breast cancer

Oct 01, 2025

marketwatch.com

AstraZeneca shares rallied on Wednesday after the U.K. giant and its Japanese partner said the Food and Drug Administration was reviewing one of its drugs to treat breast cancer.

AZN - AstraZeneca and other UK pharma boosted by Trump's first drug discount deal with Pfizer

Oct 01, 2025

proactiveinvestors.co.uk

Shares in the UK's biggest drug companies led the way on Wednesday, following news overnight that the US government had agreed its first deal on "most favoured nation" drug pricing with Pfizer. Topping the FTSE 100, Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares jumped 4% in early trading, wi

AZN - CNBC's UK Exchange newsletter: AstraZeneca gets a shot on Wall Street

Oct 01, 2025

cnbc.com

AstraZeneca is delisting its American Depositary Receipts from the Nasdaq, replacing them with a direct listing of ordinary shares on the New York Stock Exchange. At first blush, it confirms fears first aired when, in July, The Times reported that CEO Pascal Soriot wanted to move AZ's stock market l

AZN - AstraZeneca's US listing may pull other firms from London in its wake

Sep 30, 2025

reuters.com

AstraZeneca's move to upgrade its listing in the U.S. risks pulling liquidity away from London's stock market and could pave the way for other large companies to follow suit, analysts, investors and advisers said.

AZN - Pharma giant AstraZeneca eyes NYSE listing overhaul, keeps London base

Sep 30, 2025

invezz.com

AstraZeneca announced plans to change how it lists shares in the United States by moving from American depositary receipts (ADRs) on Nasdaq to a direct listing of its ordinary shares on the New York Stock Exchange.

AZN - AstraZeneca plans to list on NYSE, but will remain in the U.K.

Sep 29, 2025

fastcompany.com

AstraZeneca laid out plans on Monday to switch to a direct listing of its shares in the United States, as the drugmaker seeks to maximise gains from a booming U.S. stock market, even as it said it was not exiting London.

AZN - AstraZeneca's New York listing tweak dubbed a 'knock-back for London'

Sep 29, 2025

proactiveinvestors.co.uk

Shares in AstraZeneca PLC (LSE:AZN) rose on Monday as it shared plans to directly list its shares on the New York Stock Exchange instead of American depository shares (ADSes). The FTSE 100 pharmaceuticals group, which has flitted between being the largest and second largest company in the London ind

AZN - AstraZeneca to directly list shares in New York, retain UK listing

Sep 29, 2025

reuters.com

AstraZeneca said on Monday that it will now directly list its shares on the New York Stock Exchange, instead of the current depository shares, adding that it will continue to be listed and headquartered in the UK.

AZN - 3 Magnificent Stocks Under $100 to Buy Right Now

Sep 27, 2025

fool.com

Share price has nothing to do with whether a stock is fairly valued. However, it is nonetheless an important consideration for investors on tight budgets.

AZN - A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff

Sep 26, 2025

seekingalpha.com

Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products puts over 50% of its free cash flow at risk, despite ongoing U.S. manufacturing expansion. Sanofi's hi

AZN - AstraZeneca to Offer Discounted Drugs As Trump Pressures Pharma Industry to Cut Prices

Sep 26, 2025

wsj.com

AstraZeneca said it will offer its asthma and diabetes drugs at an up to 70% discount in the U.S. ahead of a Trump administration deadline for pharmaceutical companies to cut drug prices.

AZN - AstraZeneca to cut some direct-to-patient US drug prices after Trump demand

Sep 26, 2025

reuters.com

AstraZeneca said on Friday it will sell its diabetes and asthma drugs direct to cash-paying U.S. patients at a discount of up to 70% off list prices, the latest pharma company to do so after pressure from U.S. President Donald Trump.

AZN - Astrazeneca (AZN) Declines More Than Market: Some Information for Investors

Sep 25, 2025

zacks.com

The latest trading day saw Astrazeneca (AZN) settling at $73.53, representing a -2.43% change from its previous close.

AZN - AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold?

Sep 25, 2025

zacks.com

AstraZeneca stock is up 15% so far in 2025 as blockbuster drugs and a robust oncology portfolio fuel growth despite looming headwinds.

AZN - AZN, Daiichi's Enhertu sBLA Gets FDA Priority Review for Breast Cancer

Sep 25, 2025

zacks.com

AstraZeneca and Daiichi's Enhertu wins FDA priority review in breast cancer, backed by phase III data showing a 44% lower progression risk.

AZN - Here's Why Astrazeneca (AZN) is a Strong Growth Stock

Sep 25, 2025

zacks.com

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

AZN - AstraZeneca: Oncology Breakthroughs And Farxiga Surge Excite Investors

Sep 25, 2025

seekingalpha.com

Even with Trump's looming threats to impose tariffs on pharma imports, the performance of AstraZeneca's cardiovascular and oncology franchises continues to impress me. So, sales of Truqap, which continues to actively capture the breast cancer drugs market, reached $170 million in the second quarter

AZN - Here's Why Astrazeneca (AZN) is a Strong Value Stock

Sep 24, 2025

zacks.com

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Loading...

AstraZeneca PLC's Stock Analysis

Quarterly Income and Debt

AZN News

AZN - AstraZeneca Stock Is Up 10% on Tariff News. But Is the Pharmaceutical Giant a Buy?

AZN - Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term

AZN - AstraZeneca shares leap with FDA set to review drug to treat breast cancer

AZN - AstraZeneca and other UK pharma boosted by Trump's first drug discount deal with Pfizer

AZN - CNBC's UK Exchange newsletter: AstraZeneca gets a shot on Wall Street

AZN - AstraZeneca's US listing may pull other firms from London in its wake

AZN - Pharma giant AstraZeneca eyes NYSE listing overhaul, keeps London base

AZN - AstraZeneca plans to list on NYSE, but will remain in the U.K.

AZN - AstraZeneca's New York listing tweak dubbed a 'knock-back for London'

AZN - AstraZeneca to directly list shares in New York, retain UK listing

AZN - 3 Magnificent Stocks Under $100 to Buy Right Now

AZN - A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff

AZN - AstraZeneca to Offer Discounted Drugs As Trump Pressures Pharma Industry to Cut Prices

AZN - AstraZeneca to cut some direct-to-patient US drug prices after Trump demand

AZN - Astrazeneca (AZN) Declines More Than Market: Some Information for Investors

AZN - AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold?

AZN - AZN, Daiichi's Enhertu sBLA Gets FDA Priority Review for Breast Cancer

AZN - Here's Why Astrazeneca (AZN) is a Strong Growth Stock

AZN - AstraZeneca: Oncology Breakthroughs And Farxiga Surge Excite Investors

AZN - Here's Why Astrazeneca (AZN) is a Strong Value Stock